---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-010478"
form_type: "8-K"
ticker: "RXST"
cik: "0001111485"
company_name: "RxSight, Inc."
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:46:44.483336+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# RxSight preliminary Q4 2025 revenue ~$32.6M, FY2025 revenue ~$134.5M above guidance; appoints Mark Wilterding CFO

## Summary
- Q4 2025 revenue ~$32.6M; FY2025 revenue ~$134.5M vs prior guidance $125-130M.
- LAL procedure volume 28,611 in Q4 (+10% QoQ) and 109,615 in FY2025 (+12% YoY).
- Installed LDD base reached 1,134 as of Dec 31, 2025 (25 LDDs sold in Q4).
- Cash & short-term investments ~$228.1M as of Dec 31, 2025.
- Mark Wilterding appointed CFO effective Jan 11, 2026, replacing Shelley Thunen (consulting role).

## SEC filing metadata
- accession: 0001193125-26-010478
- form_type: 8-K
- ticker: RXST
- cik: 0001111485
- company_name: RxSight, Inc.
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1111485/000119312526010478/0001193125-26-010478-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1111485/000119312526010478/rxst-20260111.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-010478
- JSON: https://secwatch.observer/filing/0001193125-26-010478.json
- Plain text: https://secwatch.observer/filing/0001193125-26-010478.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.